NEW YORK (Reuters Health) - Sibutramine, which is marketed under the trade names Meridia and Reductil, appears safe and possibly effective for weight management in patients at a high risk for heart attack and stroke -- for whom the drug is usually not recommended -- according to a report in the European Heart Journal.